Physician profile
Avery Dinallo
NPI 1902328404
$7,984.52
in general payments reported to CMS, 2019-2025
20 companies · $6,284 in 2025
The $6,284 reported for 2025 was more than what 99% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $24.51 · 2022: $80.66 · 2023: $678 · 2024: $918 · 2025: $6,284.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,799 · Travel and Lodging: $2,552 · Consulting Fee: $2,100 · Education: $428.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,799.42 |
| Travel and Lodging | $2,551.97 |
| Consulting Fee | $2,100.00 |
| Education | $427.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Arcutis Biotherapeutics, INC. | $5,098.55 | 2024-2025 | Zoryve |
| Genzyme Corporation | $369.29 | 2022-2025 | |
| Janssen Biotech, INC. | $330.47 | 2023-2025 | Tremfya, Stelara, Simponi |
| Novartis Pharmaceuticals Corporation | $324.78 | 2023-2025 | |
| Regeneron Healthcare Solutions, INC. | $278.67 | 2022-2025 | Dupixent, Libtayo |
| Abbvie INC. | $277.83 | 2021-2025 | |
| Incyte Corporation | $219.50 | 2023-2025 | Opzelura |
| Intuitive Surgical, INC. | $197.15 | 2024-2025 | |
| E.R. Squibb & Sons, L.L.C. | $181.59 | 2023-2025 | Sotyktu, Opdivo |
| Sun Pharmaceutical Industries INC. | $171.22 | 2022-2025 | |
| Sanofi-Aventis U.S. LLC | $99.99 | 2024 | |
| Ucb, INC. | $87.29 | 2023-2025 | Bimzelx, Cimzia |
| Organon LLC | $77.78 | 2025 | Vtama |
| Galderma Laboratories, L.P. | $76.41 | 2025 | Nemluvio |
| Leo Pharma INC. | $67.02 | 2024-2025 | Adbry |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $34.44 | 2024 | Spevigo |
| Dermavant Sciences, INC. | $28.57 | 2024 | Vtama |
| Lilly USA, LLC | $23.91 | 2024 | Ebglyss |
| Amgen INC. | $22.10 | 2022 | |
| Strata Skin Sciences, INC. | $17.96 | 2023 | Xtrac |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Avery Dinallo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.